NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance (4). The fourth-quarter 2022 ...

Pfizer sold $37.8 billion of its Covid vaccine last year, a small increase of 3% compared with 2021 as demand for the shots slowed. Sales of Paxlovid, however, surged to $18.9 billion in 2022, which ...

Good day, everyone, and welcome to Pfizer’s Fourth Quarter 2022 Earnings Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, Senior ...

Pfizer is a venerable pharmaceutical company with a wide variety of existing products and a solid drug pipeline, whereas Moderna is more of a one-trick pony, having no revenues to speak of before it ...

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46. The U.S. drugmaker reported sales of $13.28 billion, up 2% ...

Super Bowl ads are a show within the show, an opportunity for brands and advertising creatives to put their work in front of more than 100 million viewers. And while the occasion is most closely ...

Dec 13 (Reuters) - Pfizer has turned to multi-billion deals, an internal restructuring and a massive cost-cutting program as the U.S. drugmaker battles a steep fall in demand for its COVID-19 products ...

Pfizer stock is the worst performing among the "Big 8" U.S. pharmaceutical companies across 5, 3, 1 year, and 3m periods. PFE released FY23 earnings yesterday - as expected - owing to a fall in COVID ...

Second-quarter 2024 Comirnaty revenues of $195 million declined 87%. Paxlovid revenues increased 79% to $251 million. Vyndaqel family drugs generated sales of $2.46 billion, up 68%. Eliquis, a blood ...